尿亮氨酸氨基肽酶对糖尿病和高血压病早期肾损害的诊断价值

The value of urine leucine aminopeptidase for diagnosing early renal injury in diabetic and hypertension patients

目的探讨尿亮氨酸氨基肽酶(LAP)筛查糖尿病和高血压病早期肾损害的临床价值。方法用本室建立的连续监测法,检测70例糖尿病患者,45例高血压患者和121名正常对照组的尿LAP,并与尿N-乙酰-β-D-氨基葡萄糖苷酶(NAG)进行比较。结果与正常对照组尿LAP31.9±8.2U/g·Cr比较,糖尿病组和高血压组尿LAP分别为36.3±14.8U/g·Cr和48.1±24.5U/g·Cr,差异有显著性意义(P<0.01)。糖尿病、高血压病尿LAP均与NAG呈显著正相关,尿LAP检测早期肾损害的特异性与NAG相近,敏感性稍低于NAG。结论尿LAP测定是筛查糖尿病和高血压早期肾损害的一项有价值的指标。

Objective To study the role of urine leucine aminopeptidase(LAP)for sifting early renal injury in diabetic and hypertension patients.Methods Urine LAP levels of70diabetic patients,45hypertension patients and121healthy subjects were detected by continuous monitoring method(estab-lished by our laboratory)and compared with urine N-acetyl-β-D-glucosaminidase(NAG).Results The levels of urine LAP in diabetic and hypertension patients increased significantly,compared with those in healthy subjects(31.9±8.2U/g·Cr vs36.3±14.8,48.1±24.5U/g·Cr,P<0.01).A significant positive correlation was noted between LAP and NAG.The specificity of LAP was similar to that of NAG,the sensitivity of LAP was lower than that of NAG for diagnosis of early renal injury.Conclusion Determination of LAP is a useful method for sifting early renal injury in diabetic and hypertension patients.